Efficacy of primary PCI: The microvessel perspective

European Heart Journal, Supplement

Volumn 7, Issue I, 2005, Pages

  Ferenc, Miroslav ^a   Neumann, Franz Josef ^a  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

Author keywords

Abciximab; Acute myocardial infarction; Microvascular perfusion; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ADENOSINE; FIBRINOGEN RECEPTOR ANTAGONIST;

ACUTE HEART INFARCTION; CELL INTERACTION; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY CONSTRICTION; HEART MUSCLE REPERFUSION; HUMAN; MICROVASCULARIZATION; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME;

EID: 26844577113     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sui061     Document Type: Review

References (69)

1. Vogt A, von Essen R, Tebbe U et al. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cordiol 1993;21: 1391-1395.
2. Simes RJ, Topol EJ, Holmes DR Jr et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation 1995;91:1923-1928.
3. Anderson JL, Karagounis LA, Becker LC et al. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Circulation 1993;87:1829-1839.
4. Ito H, Maruyama A, Iwakura K et al. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996;93:223-228.
5. Ito H, Okamura A, Iwakura K et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996;93:1993-1999.
6. Wakatsuki T, Nakamura M, Tsunoda T et al. Coronary flow velocity immediately after primary coronary stenting as a predictor of ventricular wall motion recovery in acute myocardial infarction. J Am Coll Cardiol 2000;35:1835-1841.
7. Mazur W, Bitar JN, Lechin M et al. Coronary flow reserve may predict myocardial recovery after myocardial infarction in patients with TIMI grade 3 flow. Am Heart J 1998;136:335-344.
8. Tsunoda T, Nakamura M, Wakatsuki T et al. The pattern of alteration in flow velocity in the recanalized artery is related to left ventricular recovery in patients with acute infarction and successful direct balloon angioplasty. J Am Coll Cardiol 1998;32:338-344.
9. Neumann FJ, Blasini R, Schmitt C et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998;98:2695-2701.
10. Neumann FJ, Kosa I, Dickfeld T et al. Recovery of myocardial perfusion in acute myocardial infarction after successful balloon angioplasty and stent placement in the infarct-related coronary artery. J Am Coll Cardiol 1997;30:1270-1276.
11. French JK, Hyde TA, Straznicky IT et al. Relationship between corrected TIMI frame counts at three weeks and late survival after myocardial infarction. J Am Coll Cardiol 2000;35:1516-1524.
12. Gibson CM, Murphy SA, Rizzo MJ et al. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis in Myocardial Infarction (TIMI) Study Group. Circulation 1999;99:1945-1950.
13. Gibson CM, Cannon CP, Murphy SA et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000;101:125-130.
14. van't Hof AW, Liem A, Suryapranata H et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 1998;97:2302-2306.
15. Giri S, Mitchel JF, Hirst JA et al. Synergy between intracoronary stenting and abciximab in improving angiographic and clinical outcomes of primary angioplasty in acute myocardial infarction. Am J Cardiol 2000;86:269-274.
16. Henriques JP, Zijlstra F, Ottervanger JP et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J 2002;23:1112-1117.
17. Limbruno U, Micheli A, de Carlo M et al. Mechanical prevention of distal embolization during primary angioplasty: safety, feasibility, and impact on myocardial reperfusion. Circulation 2003;108:171-176.
18. Saber RS, Edwards WD, Bailey KR et al. Coronary embolization after balloon angioplasty or thrombolytic therapy: an autopsy study of 32 cases. J Am Coll Cardiol 1993;22:1283-1288.
19. Stone GW, Webb J, Cox DA et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA 2005;293:1063-1072.
20. Gick M, Jander N, Bestehorn HP et al. Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without ST-segment elevation. Circulation 2005;112:1462-1469.
21. EMIPFR Group. Effect of 48-hour intravenous trimetazidine on short-and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy. A double-blind, placebo-controlled randomized trial. Eur Heart J 2000;21:1537-1546.
22. CORE Investigators. Effects of Rheoth Rx on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarction. Circulation 1997;96:192-201.
23. Wall TC, Califf RM, Blankenship J et al. Intravenous fluosol in the treatment of acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction 9 trial. Circulation 1994;90:114-120.
24. Faxon DP, Gibbons RJ, Chronos NA et al. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J Am Coll Cardiol 2002;40:1199-1204.
25. Baran KW, Nguyen M, McKendall GR et al. Double-blind randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction. Circulation 2001;104:2778-2783.
26. Kaminski PM, Proctor KG. Attenuation of no-reflow phenomenon, neutrophil activation, and reperfusion injury in intestinal microcirculation by topical adenosine. Circ Res 1989;65:426-435.
27. Babbitt DG, Virmani R, Forman MB. Intracoronary adenosine administered after reperfusion limits vascular injury after prolonged ischemia in the canine model. Circulation 1989;80:1388-1399.
28. Marzilli M, Orsini E, Marraccini P et al. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000;101:2154-2159.
29. Ross AM, Gibbons RJ, Stone GW et al. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005;45:1775-1780.
30. Topol EJ. Toward a new frontier in myocardial reperfusion therapy. Emerging platelet preeminence. Circulation 1998;1997:211-218.
31. Mulumudi MS, Potluri SP, White CJ. Role of abciximab in the preservation of myocardial microcirculation during mechanical reperfusion for acute ST segment elevation myocardial infarction. (Abstract). J Am Coll Cardiol 2002;39(Suppl. A):294A.
32. Petronio AS, Musumeci G, Nardi C et al. Microcirculation recovery after primary coronary angioplasty in patients with acute myocardial infarction treated with abciximab or intracoronary adenosine. (Abstract). J Am Coll Cardiol 2002;39(Suppl. A):388A.
33. Petronio AS, Rovai D, Musumeci G et al. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Eur Heart J 2003;24:67-76.
34. Simon DI, Xu H, Ortlepp S et al. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997;17:528-535.
35. Tam SH, Sassoli PM, Jordan RE et al. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation 1998;98:1085-1091.
36. Büttner HJ, Neumann FJ. Tirofiban for catheter intervention in acute myocardial infarction? Eur Heart J 2004;25:807-809.
37. Coller BS. GPIIb/IIIa antagonists: pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost 1997;78:730-735.
38. Willerson JT, Yao SK, McNatt J et al. Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury. Proc Natl Acad Sci USA 1991;88:10624-10628.
39. Morel O, Hugel B, Jesel L et al. Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists. J Thromb Haemost 2004;2:1118-1126.
40. Massberg S, Enders G, Leiderer R et al. Platelet-endothelial cell interactions during ischemia/reperfusion: the role of P-selectin. Blood 1998;92:507-515.
41. 3) mediates platelet adhesion to the luminal aspect of endothelial cells. Implications for reperfusion in acute myocardial infarction. Circulation 1997;96:1809-1818.
42. Kuijper PH, Gallardo Torres HI, van der Linden JA et al. Platelet-dependent primary hemostasis promotes selectin- and integrin-mediated neutrophil adhesion to damaged endothelium under flow conditions. Blood 1996;87:3271-3281.
43. Kirchhofer D, Riederer MA, Baumgartner HR. Specific accumulation of circulating monocytes and polymorphonuclear leukocytes on platelet thrombi in a vascular injury model. Blood 1997;89:1270-1278.
44. Hamburger S, McEver RP. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood 1990;75:550-554.
45. Rinder HM, Bonan JL, Rinder CS et al. Activated and unactivated platelet adhesion to monocytes and neutrophils. Blood 1991;78:1760-1769.
46. Rinder HM, Bonan JL, Rinder CS et al. Dynamics of leukocyte-platelet adhesion in whole blood. Blood 1991;78:1730-1737.
47. Evangelista VE, Manarini S, Rotondo S et al. Platelet/polymorphonuclear leukocyte interaction in dynamic conditions: evidence of adhesion cascade and cross talk between P-selectin and the β2 integrin CD11b/CD18. Blood 1996;88:4183-4194.
48. Diacovo TG, Roth SJ, Buccola JM et al. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the β2-integrin CD11b/CD18. Blood 1996;88:146-157.
49. Konstantopoulos K, Neelamegham S, Burns AR et al. Venous levels of shear support neutrophil-platelet adhesion and neutrophil aggregation in blood via P-selectin and β2-integrin. Circulation 1998;98:873-882.
50. Sheikh S, Nash GB. Continuous activation and deactivation of integrin CD11b/CD18 during de novo expression enables rolling neutrophils to immobilize on platelets. Blood 1996;87:5040-5050.
51. Hidari KI, Weyrich AS, Zimmerman GA et al. Engagement of P-selectin glycoprotein ligand-1 enhances tyrosine phosphorylation and activates mitogen-activated protein kinases in human neutrophils. J Biol Chem 1997;272:28750-28756.
52. Henn V, Slupsky JR, Grafe M et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-594.
53. Nagata K, Tsuji T, Todoroki N et al. Activated platelets induce superoxide anion release by monocytes and neutrophils through P-selectin (CD62). J Immunol 1993;151:3267-3273.
54. Neumann FJ, Marx N, Gawaz M et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation 1997;95:2387-2394.
55. Ott I, Neumann FJ, Gawaz M et al. Increased neutrophil-platelet interaction in patients with unstable angina. Circulation 1996;94:1239-1246.
56. Barry OP, Pratico D, Savani RC et al. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest 1998;102:136-144.
57. Nolte D, Hecht R, Schmid P et al. Role of Mac-1 and ICAM-1 in ischemia-reperfusion injury in a microcirculation model of BALB/C mice. Am J Physiol 1994;267:H1320-H1328.
58. Neumann FJ, Ott I, Gawaz M et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995;92:748-755.
59. Ma XL, Tsao PS, Lefer AM. Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion. J Clin Invest 1991;88:1237-1243.
60. Neumann FJ, Zohlnhöfer D, Fakhoury L et al. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol 1999;34:1420-1426.
61. Kupatt C, Habazettl H, Hanusch P et al. c7E3Fab reduces postischemic leukocyte-thrombocyte interaction mediated by fibrinogen. Implications for myocardial reperfusion injury. Arterioscler Thromb Vasc Biol 2000;20:2226-2232.
62. Aymong ED, Curtis MJ, Youssef M et al. Abciximab attenuates coronary microvascular endothelial dysfunction after coronary stenting. Circulation 2002;105:2981-2985.
63. Brener SJ, Barr LA, Burchenal JE et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998;98:734-741.
64. Neumann FJ, Kastrati A, Schmitt C et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000;35:915-921.
65. Montalescot G, Barragan P, Wittenberg O et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.
66. Stone GW, Grines CL, Cox DA et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-966.
67. Antoniucci D, Rodriguez A, Hempel A et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003;42:1879-1885.
68. Antoniucci D, Migliorini A, Parodi G et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation 2004;109:1704-1706.
69. de Luca G, Suryapranata H, Stone GW et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005;293:1759-1765.